245 related articles for article (PubMed ID: 31336293)
21. Balancing access and safety in prescribing opioid agonist therapy to prevent HIV transmission.
Bachireddy C; Weisberg DF; Altice FL
Addiction; 2015 Dec; 110(12):1869-71. PubMed ID: 26464200
[No Abstract] [Full Text] [Related]
22. Update on pharmacotherapy for treatment of opioid use disorder.
Ayanga D; Shorter D; Kosten TR
Expert Opin Pharmacother; 2016 Dec; 17(17):2307-2318. PubMed ID: 27734745
[TBL] [Abstract][Full Text] [Related]
23. Buprenorphine Supply, Access, and Quality: Where We Have Come and the Path Forward.
Breen CT; Fiellin DA
J Law Med Ethics; 2018 Jun; 46(2):272-278. PubMed ID: 30147002
[TBL] [Abstract][Full Text] [Related]
24. Buprenorphine-based regimens and methadone for the medical management of opioid dependence: selecting the appropriate drug for treatment.
Maremmani I; Gerra G
Am J Addict; 2010; 19(6):557-68. PubMed ID: 20958853
[TBL] [Abstract][Full Text] [Related]
25. Use and misuse of opioid agonists in opioid addiction.
Modesto-Lowe V; Swiezbin K; Chaplin M; Hoefer G
Cleve Clin J Med; 2017 May; 84(5):377-384. PubMed ID: 28530896
[TBL] [Abstract][Full Text] [Related]
26. Opioid agonist doses for oxycodone and morphine dependence: Findings from a retrospective case series.
Nielsen S; Bruno R; Degenhardt L; Demirkol A; Lintzeris N
Drug Alcohol Rev; 2017 May; 36(3):311-316. PubMed ID: 27273511
[TBL] [Abstract][Full Text] [Related]
27. Addiction Treatment Within U.S. Correctional Facilities: Bridging the Gap Between Current Practice and Evidence-Based Care.
Wakeman SE; Rich JD
J Addict Dis; 2015; 34(2-3):220-5. PubMed ID: 26076211
[TBL] [Abstract][Full Text] [Related]
28. Diversion of methadone and buprenorphine from opioid substitution treatment: a staff perspective.
Johnson B; Richert T
J Psychoactive Drugs; 2014; 46(5):427-35. PubMed ID: 25364995
[TBL] [Abstract][Full Text] [Related]
29. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder.
Fox AD; Maradiaga J; Weiss L; Sanchez J; Starrels JL; Cunningham CO
Addict Sci Clin Pract; 2015 Jan; 10(1):2. PubMed ID: 25592182
[TBL] [Abstract][Full Text] [Related]
30. The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone.
Stein BD; Gordon AJ; Sorbero M; Dick AW; Schuster J; Farmer C
Drug Alcohol Depend; 2012 Jun; 123(1-3):72-8. PubMed ID: 22093488
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Treatment Options for Refractory Opioid Use Disorder in the United States and Canada: a Narrative Review.
Kimmel S; Bach P; Walley AY
J Gen Intern Med; 2020 Aug; 35(8):2418-2426. PubMed ID: 32462569
[TBL] [Abstract][Full Text] [Related]
32. Reframing the Prevention Strategies of the Opioid Crisis: Focusing on Prescription Opioids, Fentanyl, and Heroin Epidemic.
Manchikanti L; Sanapati J; Benyamin RM; Atluri S; Kaye AD; Hirsch JA
Pain Physician; 2018 Jul; 21(4):309-326. PubMed ID: 30045589
[TBL] [Abstract][Full Text] [Related]
33. Relationship of County Opioid Epidemic Severity to Changes in Access to Substance Use Disorder Treatment, 2009-2017.
Yarbrough CR; Abraham AJ; Adams GB
Psychiatr Serv; 2020 Jan; 71(1):12-20. PubMed ID: 31575353
[TBL] [Abstract][Full Text] [Related]
34. Revising our attitudes towards agonist medications and their diversion in a time of pandemic.
Del Pozo B; Rich JD
J Subst Abuse Treat; 2020 Dec; 119():108139. PubMed ID: 33138924
[TBL] [Abstract][Full Text] [Related]
35. Office-Based Buprenorphine Versus Clinic-Based Methadone: A Cost-Effectiveness Analysis.
King JB; Sainski-Nguyen AM; Bellows BK
J Pain Palliat Care Pharmacother; 2016; 30(1):55-65. PubMed ID: 27007583
[TBL] [Abstract][Full Text] [Related]
36. Novel Therapeutic and Program-Based Approaches to Opioid Use Disorders.
Liu P; Korthuis PT; Buchheit BM
Annu Rev Med; 2024 Jan; 75():83-97. PubMed ID: 37827194
[TBL] [Abstract][Full Text] [Related]
37. Challenges and Opportunities for the Use of Medications to Treat Opioid Addiction in the United States and Other Nations of the World.
Parrino MW; Maremmani AG; Samuels PN; Maremmani I
J Addict Dis; 2015; 34(2-3):255-62. PubMed ID: 26110357
[TBL] [Abstract][Full Text] [Related]
38. Methadone versus buprenorphine for the treatment of opioid abuse in pregnancy: science and stigma.
Holbrook AM
Am J Drug Alcohol Abuse; 2015; 41(5):371-3. PubMed ID: 26154531
[TBL] [Abstract][Full Text] [Related]
39. Long-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: the case of Sweden.
Richert T; Johnson B
Harm Reduct J; 2015 Feb; 12():1. PubMed ID: 25889208
[TBL] [Abstract][Full Text] [Related]
40. Buprenorphine MAT as an Imperfect Fix.
Mund B; Stith K
J Law Med Ethics; 2018 Jun; 46(2):279-291. PubMed ID: 30147005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
